France grants early access to Janssen's ibrutinib for CLL & MCL
This article was originally published in Scrip
The French regulator, ANSM, has approved an early access program for Janssen's ibrutinib in the treatment of chronic lymphocytic leukaemia (CLL) and mantle cell lymphoma (MCL), pending its approval via the EU's centralized procedure.
You may also be interested in...
Efforts are under way in the UK on many fronts to develop new treatments and vaccines for coronavirus infection, including researching new uses of existing products and clinical trials of new vaccines.
Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.
AMD patients in the UK can legitimately be given compounded bevacizumab (Roche’s Avastin) after the appeals court said NHS trusts could offer a drug off-label for economic reasons where there were no safety or efficacy concerns.